Category: Finance
-
Infographic – 2022 Biotech Venture Funding Weakens
Venture funds for new U.S. biotechnology and pharmaceutical companies declined from historical highs in 2022, but a closer look reveals even more signs of financial tightening.
-
Environmental Biomarker Start-Up Gains $16M in Early Funds
A new company developing diagnostics for neurological and other disorders based on environmental exposures is raising $16 million in venture funds.
-
CEPI Assessing Advanced RNA Nanoparticle Vaccine
An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics.
-
Audio Digital Biomarkers Start-Up Raises $3.7M in Seed Funds
A new company developing techniques to analyze internal physiological sounds captured by stethoscopes as health indicators is raising $3.7 million in seed funds.
-
Infographic – Mixed Signals on 2022 Venture Funding
Total venture funds invested fell each quarter in 2022, from $163.1 billion in Q1 to $77.2 billion in Q4, which suggests continued declines into 2023.
-
Protein Chemistry Biotech Gains Collaboration, Venture Funds
An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech.
-
Infographic – Biotech Index Struggles to Regain Ground
NBI is showing signs of life, rising somewhat from its low point for the year and since the end of the third quarter, but still down almost 12 percent since the start of the year.
-
Infographic – Cancer Start-Up Venture Funds Decline
Funding for new enterprises creating products and services that treat or detect cancer fell more than 40 percent from last year.
-
Food Protein Biotech Adds €4M in Seed Funds
A new company creating protein ingredients for food products from carbon dioxide converted by engineered bacteria is raising €4 million more in seed funds.
-
Cell Biology Tools Companies Merge in $57.8M Deal
Two providers of technologies for cellular analysis are merging to form a new company focusing on cell biology research tools, in a sign of continued industry consolidation.